ES2174176T3 - Procedimiento para reducir el daño en tejido asociado con la isquemia. - Google Patents

Procedimiento para reducir el daño en tejido asociado con la isquemia.

Info

Publication number
ES2174176T3
ES2174176T3 ES97200415T ES97200415T ES2174176T3 ES 2174176 T3 ES2174176 T3 ES 2174176T3 ES 97200415 T ES97200415 T ES 97200415T ES 97200415 T ES97200415 T ES 97200415T ES 2174176 T3 ES2174176 T3 ES 2174176T3
Authority
ES
Spain
Prior art keywords
ischemia
procedure
tissue damage
damage associated
reduce tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97200415T
Other languages
English (en)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2174176T3 publication Critical patent/ES2174176T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

USO DE UN INHIBIDOR DE DEHIDROGENASA DE SORBITOL PARA LA FABRICACION DE UN MEDICAMENTO QUE REDUZCA EL DAÑO TISULAR DERIVADO DE LA ISQUEMIA EN UN MAMIFERO (INCLUIDO EL SER HUMANO).
ES97200415T 1996-02-29 1997-02-13 Procedimiento para reducir el daño en tejido asociado con la isquemia. Expired - Lifetime ES2174176T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270896P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
ES2174176T3 true ES2174176T3 (es) 2002-11-01

Family

ID=21756305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97200415T Expired - Lifetime ES2174176T3 (es) 1996-02-29 1997-02-13 Procedimiento para reducir el daño en tejido asociado con la isquemia.

Country Status (15)

Country Link
US (1) US5932581A (es)
EP (1) EP0791355B1 (es)
JP (1) JPH09316004A (es)
KR (1) KR100219972B1 (es)
CN (1) CN1165000A (es)
AT (1) ATE216226T1 (es)
AU (1) AU714038B2 (es)
CA (1) CA2198536C (es)
DE (1) DE69711965T2 (es)
DK (1) DK0791355T3 (es)
ES (1) ES2174176T3 (es)
IL (1) IL120271A (es)
MY (1) MY118982A (es)
PT (1) PT791355E (es)
ZA (1) ZA971715B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366858A1 (en) * 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CN104346404B (zh) * 2013-08-08 2018-05-18 华为技术有限公司 一种访问数据的方法、设备及系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE4025387A1 (de) 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
NZ254550A (en) 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications

Also Published As

Publication number Publication date
DE69711965T2 (de) 2003-01-23
AU714038B2 (en) 1999-12-16
ZA971715B (en) 1998-08-27
KR100219972B1 (ko) 1999-09-01
ATE216226T1 (de) 2002-05-15
US5932581A (en) 1999-08-03
MY118982A (en) 2005-02-28
KR970061257A (ko) 1997-09-12
CN1165000A (zh) 1997-11-19
JPH09316004A (ja) 1997-12-09
CA2198536A1 (en) 1997-08-29
DK0791355T3 (da) 2002-06-17
MX9701527A (es) 1998-06-30
EP0791355B1 (en) 2002-04-17
DE69711965D1 (de) 2002-05-23
AU1500997A (en) 1997-09-04
IL120271A (en) 2001-06-14
CA2198536C (en) 2000-06-20
EP0791355A1 (en) 1997-08-27
PT791355E (pt) 2002-08-30
IL120271A0 (en) 1997-06-10

Similar Documents

Publication Publication Date Title
AR009626A1 (es) Una composicion dermatologica o cosmetica que comprende una cantidad de esfingomielinasa efectiva para producir un aumento en el nivel de las ceramidas de la piel y de la mucosa.
ES2107762T3 (es) Utilizacion de un alquilester de glutation en una composicion cosmetica o dermatologica destinada al tratamiento por via topica del envejecimiento cutaneo.
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
MX9702272A (es) Inhibicion del crecimiento del cabello.
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
AR002292A1 (es) Espuma de poliuretano flexible, proceso para su preparacion y sistema de reaccion.
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
EE03975B1 (et) Keratinotsüüdi kasvufaktori analoogid
ES2000880A6 (es) Un procedimiento para preparar n-(1(s)-etoxicarbonil-3-fenilpropil)-l-alanil-l-prolina
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
ES2192680T3 (es) Nuevos derivados de vitamina d con sustituyentes carbo- o heterociclicos en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
DK0460062T3 (da) Huperzin A-analoger
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2062138T3 (es) Utilizacion de 5'-deoxi-5'-metiltioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas favorecedoras del crecimiento del cabello en sujetos adolecientes de calvicie.
AR004330A1 (es) Uso de inhibidores de colinesterasa en el tratamiento de xerostomia
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
PT791355E (pt) Metodo para diminuir os daos associados com a isquemia nos tecidos
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
ES2187727T3 (es) Medicamentos y cosmeticos que comprenden extractos de zizyphus spina-christi.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 791355

Country of ref document: ES